Do analysts prefer ADXN or EVFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer ADXN or EVFM?

In the previous week, Addex Therapeutics had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for Addex Therapeutics and 1 mentions for Evofem Biosciences. Addex Therapeutics' average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evofem Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend EVFM or SBFM?

Sunshine Biopharma has a consensus target price of $70.00, suggesting a potential upside of 7,892.69%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than Evofem Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate EVFM or GRI?

GRI Bio has a consensus target price of $21.00, indicating a potential upside of 876.74%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Evofem Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GRI Bio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is EVFM or GRI more profitable?

GRI Bio has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets Evofem Biosciences -46.42% -91.97% -61.93% GRI Bio N/A -134.03% -106.83%

Do analysts recommend CVKD or EVFM?

Cadrenal Therapeutics currently has a consensus price target of $13.00, indicating a potential upside of 884.85%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Cadrenal Therapeutics is more favorable than Evofem Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor CVKD or EVFM?

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for Evofem Biosciences. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Evofem Biosciences' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evofem Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate REVB or EVFM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Evofem Biosciences (EVFM) Competitors

$0.0077 0.00 (0.00%)

As of 09/23/2026 02:27 PM Eastern

Compare

EVFM vs. ADXN, SBFM, GRI, CVKD, and REVB

Should you buy Evofem Biosciences stock or one of its competitors? Evofem Biosciences's main competitors and comparable companies include Addex Therapeutics (ADXN), Sunshine Biopharma (SBFM), GRI Bio (GRI), Cadrenal Therapeutics (CVKD), and Revelation Biosciences (REVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Evofem Biosciences compare to Addex Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Addex Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

Addex Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.3, suggesting that its stock price is 230% less volatile than the broader market.

In the previous week, Addex Therapeutics had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for Addex Therapeutics and 1 mentions for Evofem Biosciences. Addex Therapeutics' average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evofem Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evofem Biosciences has higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$29.97K	141.81	-$8.12M	-$5.94	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Addex Therapeutics beats Evofem Biosciences on 7 of the 13 factors compared between the two stocks.

How does Evofem Biosciences compare to Sunshine Biopharma?

Evofem Biosciences (NASDAQ:EVFM) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Evofem Biosciences has a beta of -1.3, indicating that its share price is 230% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sunshine Biopharma has a net margin of -17.94% compared to Evofem Biosciences' net margin of -46.42%. Sunshine Biopharma's return on equity of -26.36% beat Evofem Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

In the previous week, Evofem Biosciences had 1 more articles in the media than Sunshine Biopharma. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Sunshine Biopharma. Evofem Biosciences' average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Evofem Biosciences	Neutral
Sunshine Biopharma	Neutral

Sunshine Biopharma has a consensus target price of $70.00, suggesting a potential upside of 7,892.69%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evofem Biosciences has higher earnings, but lower revenue than Sunshine Biopharma. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A
Sunshine Biopharma	$36.31M	0.10	-$5.97M	-$10.15	N/A

Summary

Sunshine Biopharma beats Evofem Biosciences on 11 of the 15 factors compared between the two stocks.

How does Evofem Biosciences compare to GRI Bio?

Evofem Biosciences (NASDAQ:EVFM) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

0.2% of Evofem Biosciences shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 0.0% of Evofem Biosciences shares are owned by company insiders. Comparatively, 8.7% of GRI Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Evofem Biosciences has a beta of -1.3, indicating that its share price is 230% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market.

Evofem Biosciences has higher revenue and earnings than GRI Bio. Evofem Biosciences is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A

GRI Bio has a consensus target price of $21.00, indicating a potential upside of 876.74%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

GRI Bio has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evofem Biosciences	-46.42%	-91.97%	-61.93%
GRI Bio	N/A	-134.03%	-106.83%

In the previous week, Evofem Biosciences had 1 more articles in the media than GRI Bio. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for GRI Bio. Evofem Biosciences' average media sentiment score of 0.00 equaled GRI Bio'saverage media sentiment score.

Company	Overall Sentiment
Evofem Biosciences	Neutral
GRI Bio	Neutral

Summary

Evofem Biosciences and GRI Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Evofem Biosciences compare to Cadrenal Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Cadrenal Therapeutics has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cadrenal Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.3, suggesting that its stock price is 230% less volatile than the broader market.

Evofem Biosciences has higher revenue and earnings than Cadrenal Therapeutics. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A

Cadrenal Therapeutics currently has a consensus price target of $13.00, indicating a potential upside of 884.85%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Cadrenal Therapeutics is more favorable than Evofem Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cadrenal Therapeutics had 1 more articles in the media than Evofem Biosciences. MarketBeat recorded 2 mentions for Cadrenal Therapeutics and 1 mentions for Evofem Biosciences. Cadrenal Therapeutics' average media sentiment score of 0.99 beat Evofem Biosciences' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evofem Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cadrenal Therapeutics beats Evofem Biosciences on 9 of the 15 factors compared between the two stocks.

How does Evofem Biosciences compare to Revelation Biosciences?

Revelation Biosciences (NASDAQ:REVB) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Revelation Biosciences has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-100.19%	-82.72%
Evofem Biosciences	-46.42%	-91.97%	-61.93%

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 4.8% of Revelation Biosciences shares are held by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Revelation Biosciences has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market. Comparatively, Evofem Biosciences has a beta of -1.3, indicating that its stock price is 230% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evofem Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Evofem Biosciences has higher revenue and earnings than Revelation Biosciences. Revelation Biosciences is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$8.91M	-$12.31	N/A
Evofem Biosciences	$11.39M	0.09	$52.98M	-$0.13	N/A

In the previous week, Evofem Biosciences had 1 more articles in the media than Revelation Biosciences. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for Revelation Biosciences. Revelation Biosciences' average media sentiment score of 0.00 equaled Evofem Biosciences'average media sentiment score.

Company	Overall Sentiment
Revelation Biosciences	Neutral
Evofem Biosciences	Neutral

Summary

Evofem Biosciences beats Revelation Biosciences on 7 of the 12 factors compared between the two stocks.

Get Evofem Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVFM vs. The Competition

Export

Metric	Evofem Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.02M	$12.61B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.01	792.28	274.10	25.70
Price / Sales	0.09	857.09	672.61	90.85
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.00	10.57	10.48	6.32
Net Income	$52.98M	$2.81B	$3.49B	$359.73M
7 Day Performance	N/A	-0.17%	-0.68%	0.17%
1 Month Performance	N/A	-1.39%	-3.18%	-3.27%
1 Year Performance	N/A	2.83%	15.13%	5.58%

Evofem Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVFM Evofem Biosciences	N/A	$0.01 flat	N/A	-46.9%	$1.02M	$11.39M	N/A	120	News Coverage Gap Down
ADXN Addex Therapeutics	0.6504 of 5 stars	$3.36 +3.1%	N/A	-61.8%	$4.02M	$210K	N/A	30	News Coverage
SBFM Sunshine Biopharma	2.0994 of 5 stars	$1.03 flat	$70.00 +6,696.1%	-94.5%	$3.99M	$36.31M	N/A	3	Positive News
GRI GRI Bio	2.7597 of 5 stars	$1.81 -0.5%	$21.00 +1,060.2%	-96.1%	$3.98M	N/A	N/A	1
CVKD Cadrenal Therapeutics	2.6901 of 5 stars	$1.08 +2.9%	$13.00 +1,103.7%	-90.4%	$3.75M	N/A	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVFM) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evofem Biosciences (EVFM) Competitors

EVFM vs. ADXN, SBFM, GRI, CVKD, and REVB

How does Evofem Biosciences compare to Addex Therapeutics?

Summary

How does Evofem Biosciences compare to Sunshine Biopharma?

Summary

How does Evofem Biosciences compare to GRI Bio?

Summary

How does Evofem Biosciences compare to Cadrenal Therapeutics?

Summary

How does Evofem Biosciences compare to Revelation Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM vs. The Competition

Evofem Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evofem Biosciences (EVFM) Competitors

EVFM vs. ADXN, SBFM, GRI, CVKD, and REVB

How does Evofem Biosciences compare to Addex Therapeutics?

Is ADXN or EVFM more profitable?

Which has more volatility and risk, ADXN or EVFM?

Does the media prefer ADXN or EVFM?

Which has better valuation and earnings, ADXN or EVFM?

Do analysts prefer ADXN or EVFM?

Do insiders and institutionals believe in ADXN or EVFM?

Summary

How does Evofem Biosciences compare to Sunshine Biopharma?

Which has more risk and volatility, EVFM or SBFM?

Do insiders & institutionals hold more shares of EVFM or SBFM?

Is EVFM or SBFM more profitable?

Does the media refer more to EVFM or SBFM?

Do analysts recommend EVFM or SBFM?

Which has better earnings & valuation, EVFM or SBFM?

Summary

How does Evofem Biosciences compare to GRI Bio?

Do insiders and institutionals believe in EVFM or GRI?

Which has more volatility & risk, EVFM or GRI?

Which has preferable earnings and valuation, EVFM or GRI?

Do analysts rate EVFM or GRI?

Is EVFM or GRI more profitable?

Does the media prefer EVFM or GRI?

Summary

How does Evofem Biosciences compare to Cadrenal Therapeutics?

Is CVKD or EVFM more profitable?

Do insiders and institutionals believe in CVKD or EVFM?

Which has more risk & volatility, CVKD or EVFM?

Which has stronger earnings & valuation, CVKD or EVFM?

Do analysts recommend CVKD or EVFM?

Does the media favor CVKD or EVFM?

Summary

How does Evofem Biosciences compare to Revelation Biosciences?

Is REVB or EVFM more profitable?

Do insiders & institutionals hold more shares of REVB or EVFM?

Which has more risk & volatility, REVB or EVFM?

Do analysts rate REVB or EVFM?

Which has preferable earnings and valuation, REVB or EVFM?

Does the media refer more to REVB or EVFM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVFM vs. The Competition

Evofem Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools